Uncategorised - European Medical Journal

Rheumatoid and Psoriatic Arthritis Patients Face Higher Risk of Lung Disease

RA and PsA patients face higher interstitial lung disease risk, but methotrexate does not increase this risk, study finds.

New Endometrial Cancer Screening Approach Shows Promise

Simultaneous endometrial aspiration and sonohysterography offer a highly sensitive screening approach for detecting endometrial cancer

Induction Chemotherapy Improves Survival in Locally Advanced Cervical Cancer

A new phase 3 trial (INTERLACE) shows that adding induction chemotherapy to standard chemoradiotherapy improves both progression-free and overall survival in patients with locally advanced cervical cancer.

AI Model Uncovers Key Driver of Disease-Microbiome Associations

Novel research has challenged conventional thinking around microbial associations with diseases like inflammatory bowel disease and colorectal cancer.

Onc Now: Episode 5: The Role of RNA in Oncology – Part 2

Sarah Blagden, pioneer in experimental oncology, returns to the Onc Now podcast to discuss cancer prediction and prevention, and the future of cancer vaccines.

Angiotensin Receptor Blockers May Worsen Coeliac Disease Outcomes

Findings indicated that patients taking ARBs had a higher likelihood of experiencing persistent symptoms and markers of poor small bowel healing.

COVID-19 Linked to Long-Term Connective Tissue Disorder Risks

The findings suggest that healthcare systems must prioritise post-COVID-19 care, with a focus on identifying and managing autoimmune and autoinflammatory disorders.

Inebilizumab Targets IgG4 Disease Flares

Inebilizumab, a CD19+ B-cell depleting therapy, can reduce flares and promote remission in patients with IgG4-related disease (IgG4-RD) according to the results of a new Phase III clinical trial.

Machine Learning Models Predict Success in Stopping Renal Replacement Therapy

Machine learning identifies key factors and predicts success in renal replacement therapy discontinuation for critically ill patients with acute kidney injury.

world in hands

Novartis takes the top spot in 2024 Access to Medicine Index

Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.